151 related articles for article (PubMed ID: 35365586)
1. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
[TBL] [Abstract][Full Text] [Related]
2. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.
Valero C; Golkaram M; Vos JL; Xu B; Fitzgerald C; Lee M; Kaplan S; Han CY; Pei X; Sarkar R; Boe LA; Pandey A; Koh ES; Zuur CL; Solit DB; Pawlowski T; Liu L; Ho AL; Chowell D; Riaz N; Chan TA; Morris LG
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561583
[TBL] [Abstract][Full Text] [Related]
3. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
Boichard A; Wagner MJ; Kurzrock R
Genome Med; 2020 Jul; 12(1):61. PubMed ID: 32646514
[TBL] [Abstract][Full Text] [Related]
4. A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
Jiang Z; Zhou Y; Huang J
Front Immunol; 2021; 12():813331. PubMed ID: 35003141
[TBL] [Abstract][Full Text] [Related]
5. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.
Yang RK; Qing Y; Jelloul FZ; Routbort MJ; Wang P; Shaw K; Zhang J; Lee J; Medeiros LJ; Kopetz S; Tetzlaff MT; Broaddus RR
Oncotarget; 2020 Feb; 11(6):600-618. PubMed ID: 32110280
[TBL] [Abstract][Full Text] [Related]
6. The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
Buisseret L; Bareche Y; Venet D; Girard E; Gombos A; Emonts P; Majjaj S; Rouas G; Serra M; Debien V; Agostinetto E; Garaud S; Willard-Gallo K; Larsimont D; Stagg J; Rothé F; Sotiriou C
ESMO Open; 2024 May; 9(5):102964. PubMed ID: 38703428
[TBL] [Abstract][Full Text] [Related]
7. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
[TBL] [Abstract][Full Text] [Related]
8. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Inoue Y; Inui N; Karayama M; Asada K; Fujii M; Matsuura S; Uto T; Hashimoto D; Matsui T; Ikeda M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Suda T
Cancer Immunol Immunother; 2023 Aug; 72(8):2717-2728. PubMed ID: 37099186
[TBL] [Abstract][Full Text] [Related]
9. Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure.
Huang SC; Chang IY; Chang CJ; Liu H; Chen KH; Liu TT; Hsieh TY; Chuang HC; Chen CC; Lin IC; Ng KF; Huang HY; Chen TC
J Pathol; 2023 Jun; 260(2):165-176. PubMed ID: 36815532
[TBL] [Abstract][Full Text] [Related]
10. Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers.
Diplas BH; Ptashkin R; Chou JF; Sabwa S; Foote MB; Rousseau B; Argilés G; White JR; Stewart CM; Bolton K; Chalasani SB; Desai AM; Goldberg Z; Gu P; Li J; Shcherba M; Zervoudakis A; Cercek A; Yaeger R; Segal NH; Ilson DH; Ku GY; Zehir A; Capanu M; Janjigian YY; Diaz LA; Maron SB
JAMA Netw Open; 2023 Feb; 6(2):e2254221. PubMed ID: 36729457
[TBL] [Abstract][Full Text] [Related]
11. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response.
Guo YA; Kulshrestha T; Chang MM; Kassam I; Revkov E; Rizzetto S; Tan AC; Tan DSW; Tan IB; Skanderup AJ
Cancer Res Commun; 2024 May; ():. PubMed ID: 38722600
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.
Cheung LS; Chen L; Oke TF; Schaffer TB; Boudadi K; Ngo JT; Gross JM; Kemberling H; Diaz LA; Lipson E; Sidhom JW; Taube J; Anders R; Pardoll DM; Le DT; Meyer CF; Llosa N
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103354
[TBL] [Abstract][Full Text] [Related]
14. Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.
Zhang H; Lee S; Muthakana RR; Lu B; Boone DN; Lee D; Wang XS
Cancer Immunol Res; 2024 Mar; 12(3):287-295. PubMed ID: 38345376
[TBL] [Abstract][Full Text] [Related]
15. Lack of TGFβ signaling competency predicts conversion of immune poor cancer to immune rich and response to checkpoint blockade.
Moore J; Gkantalis J; Guix I; Chou W; Yuen K; Lazar AA; Spitzer M; Combes AJ; Barcellos-Hoff MH
bioRxiv; 2024 Mar; ():. PubMed ID: 38496519
[TBL] [Abstract][Full Text] [Related]
16. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies.
Wilson BE; Routy B; Nagrial A; Chin VT
Cancer Immunol Immunother; 2020 Mar; 69(3):343-354. PubMed ID: 31865400
[TBL] [Abstract][Full Text] [Related]
17. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.
Maleki Vareki S
J Immunother Cancer; 2018 Dec; 6(1):157. PubMed ID: 30587233
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutational burden as a predictor of immunotherapy response in breast cancer.
O'Meara TA; Tolaney SM
Oncotarget; 2021 Mar; 12(5):394-400. PubMed ID: 33747355
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors.
McLean LS; Lim AM; Angel C; Young RJ; Pizzolla A; Archer S; Solomon BJ; Thai AA; Lewin J; Rischin D
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672534
[TBL] [Abstract][Full Text] [Related]
20. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade.
Gu SS; Wang X; Hu X; Jiang P; Li Z; Traugh N; Bu X; Tang Q; Wang C; Zeng Z; Fu J; Meyer C; Zhang Y; Cejas P; Lim K; Wang J; Zhang W; Tokheim C; Sahu AD; Xing X; Kroger B; Ouyang Z; Long H; Freeman GJ; Brown M; Liu XS
Genome Biol; 2020 Oct; 21(1):263. PubMed ID: 33059736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
